ARDC Research Link Australia

ORCID Profile
Orcid icon. 0000-0003-0745-7559

Current Organisations
Institut Pasteur , Hôpitaux Universitaires Henri-Mondor , Institut Mondor de recherche biomédicale , Universite Paris-Est Creteil Val de Marne , Université de Rennes 1 , Université Paris Descartes , Université Paris Diderot , Université Paris-Est Créteil Val de Marne Faculté de médecine , Université Paris-Sud

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.

Publications

Publication

Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

Publisher: Elsevier BV

Date: 05-2022

DOI: 10.1016/J.JHEPR.2022.100462

Publication

Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus

Publisher: Wiley

Date: 07-06-2011

DOI: 10.1111/J.1478-3231.2010.02373.X

Abstract: Most of the estimated 350 million people with chronic hepatitis B virus (HBV) infection live in resource-constrained settings. Up to 25% of those persons will die prematurely of hepatocellular carcinoma (HCC) or cirrhosis. Universal hepatitis B immunization programmes that target infants will have an impact on HBV-related deaths several decades after their introduction. Antiviral agents active against HBV are available treatment of HBV infection in those who need it has been shown to reduce the risk of HCC and death. It is estimated that 20-30% of persons with HBV infection could benefit from treatment. However, drugs active against HBV are not widely available or utilized in persons infected with HBV. Currently recommended antiviral agents used for treatment of human immunodeficiency virus (HIV) infection do not adequately suppress HBV, which is of great concern for the estimated 10% of the HIV-infected persons in Africa who are co-infected with HBV. Progressive liver disease has been shown to occur in co-infected persons whose HBV infection is not suppressed. In view of these concerns, an informal World Health Organization consultation of experts concluded that: chronic HBV is a major public health problem in emerging nations all HIV-infected persons should be screened for HBV infection HIV/HBV co-infected persons should be treated with therapies active against both viruses and that reduce the risk of resistance standards for the management of chronic HBV infection should be adapted to resource-constrained settings. In addition, a research agendum was developed focusing on issues related to prevention and treatment of chronic HBV in resource-constrained settings.

Publication

SHARED: An International Collaboration to Unravel Hepatitis C Resistance

Publisher: MDPI AG

Date: 10-08-2021

DOI: 10.3390/V13081580

Location: Australia

View Organisation

Related Funding Activities

No related grants have been discovered for Jean-Michel Pawlotsky.

Jean-Michel Pawlotsky

Researcher

Related Links

Publications

Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals

Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus

SHARED: An International Collaboration to Unravel Hepatitis C Resistance

Related Organisations

Institut Pasteur

Hôpitaux Universitaires Henri-Mondor

Institut Mondor De Recherche Biomédicale

Universite Paris-Est Creteil Val De Marne

Université De Rennes 1

Université Paris Descartes

Université Paris Diderot

Université Paris-Est Créteil Val De Marne Faculté De Médecine

Université Paris-Sud

University Of Melbourne

Related Funding Activities

ARDC NEWSLETTER SIGNUP